Cargando…

BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19

Vaccines against the severe acute respiratory syndrome coronavirus 2, which have been in urgent need and development since the beginning of 2020, are aimed to induce a prominent immune system response capable of recognizing and fighting future infection. Here we analyzed the levels of IgG antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaznadzey, Anna, Tutukina, Maria, Bessonova, Tatiana, Kireeva, Maria, Mazo, Ilya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044856/
https://www.ncbi.nlm.nih.gov/pubmed/35493476
http://dx.doi.org/10.3389/fimmu.2022.797918
_version_ 1784695193473122304
author Kaznadzey, Anna
Tutukina, Maria
Bessonova, Tatiana
Kireeva, Maria
Mazo, Ilya
author_facet Kaznadzey, Anna
Tutukina, Maria
Bessonova, Tatiana
Kireeva, Maria
Mazo, Ilya
author_sort Kaznadzey, Anna
collection PubMed
description Vaccines against the severe acute respiratory syndrome coronavirus 2, which have been in urgent need and development since the beginning of 2020, are aimed to induce a prominent immune system response capable of recognizing and fighting future infection. Here we analyzed the levels of IgG antibodies against the receptor-binding domain (RBD) of the viral spike protein after the administration of three types of popular vaccines, BNT162b2, mRNA-1273, or Sputnik V, using the same ELISA assay to compare their effects. An efficient immune response was observed in the majority of cases. The obtained ranges of signal values were wide, presumably reflecting specific features of the immune system of individuals. At the same time, these ranges were comparable among the three studied vaccines. The anti-RBD IgG levels after vaccination were also similar to those in the patients with moderate/severe course of the COVID-19, and significantly higher than in the individuals with asymptomatic or light symptomatic courses of the disease. No significant correlation was observed between the levels of anti-RBD IgG and sex or age of the vaccinated individuals. The signals measured at different time points for several individuals after full Sputnik V vaccination did not have a significant tendency to lower within many weeks. The rate of neutralization of the interaction of the RBD with the ACE2 receptor after vaccination with Sputnik V was on average slightly higher than in patients with a moderate/severe course of COVID-19. The importance of the second dose administration of the two-dose Sputnik V vaccine was confirmed: while several individuals had not developed detectable levels of the anti-RBD IgG antibodies after the first dose of Sputnik V, after the second dose the antibody signal became positive for all tested individuals and raised on average 5.4 fold. Finally, we showed that people previously infected with SARS-CoV-2 developed high levels of antibodies, efficiently neutralizing interaction of RBD with ACE2 after the first dose of Sputnik V, with almost no change after the second dose.
format Online
Article
Text
id pubmed-9044856
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90448562022-04-28 BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19 Kaznadzey, Anna Tutukina, Maria Bessonova, Tatiana Kireeva, Maria Mazo, Ilya Front Immunol Immunology Vaccines against the severe acute respiratory syndrome coronavirus 2, which have been in urgent need and development since the beginning of 2020, are aimed to induce a prominent immune system response capable of recognizing and fighting future infection. Here we analyzed the levels of IgG antibodies against the receptor-binding domain (RBD) of the viral spike protein after the administration of three types of popular vaccines, BNT162b2, mRNA-1273, or Sputnik V, using the same ELISA assay to compare their effects. An efficient immune response was observed in the majority of cases. The obtained ranges of signal values were wide, presumably reflecting specific features of the immune system of individuals. At the same time, these ranges were comparable among the three studied vaccines. The anti-RBD IgG levels after vaccination were also similar to those in the patients with moderate/severe course of the COVID-19, and significantly higher than in the individuals with asymptomatic or light symptomatic courses of the disease. No significant correlation was observed between the levels of anti-RBD IgG and sex or age of the vaccinated individuals. The signals measured at different time points for several individuals after full Sputnik V vaccination did not have a significant tendency to lower within many weeks. The rate of neutralization of the interaction of the RBD with the ACE2 receptor after vaccination with Sputnik V was on average slightly higher than in patients with a moderate/severe course of COVID-19. The importance of the second dose administration of the two-dose Sputnik V vaccine was confirmed: while several individuals had not developed detectable levels of the anti-RBD IgG antibodies after the first dose of Sputnik V, after the second dose the antibody signal became positive for all tested individuals and raised on average 5.4 fold. Finally, we showed that people previously infected with SARS-CoV-2 developed high levels of antibodies, efficiently neutralizing interaction of RBD with ACE2 after the first dose of Sputnik V, with almost no change after the second dose. Frontiers Media S.A. 2022-04-13 /pmc/articles/PMC9044856/ /pubmed/35493476 http://dx.doi.org/10.3389/fimmu.2022.797918 Text en Copyright © 2022 Kaznadzey, Tutukina, Bessonova, Kireeva and Mazo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Kaznadzey, Anna
Tutukina, Maria
Bessonova, Tatiana
Kireeva, Maria
Mazo, Ilya
BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19
title BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19
title_full BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19
title_fullStr BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19
title_full_unstemmed BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19
title_short BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19
title_sort bnt162b2, mrna-1273, and sputnik v vaccines induce comparable immune responses on a par with severe course of covid-19
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044856/
https://www.ncbi.nlm.nih.gov/pubmed/35493476
http://dx.doi.org/10.3389/fimmu.2022.797918
work_keys_str_mv AT kaznadzeyanna bnt162b2mrna1273andsputnikvvaccinesinducecomparableimmuneresponsesonaparwithseverecourseofcovid19
AT tutukinamaria bnt162b2mrna1273andsputnikvvaccinesinducecomparableimmuneresponsesonaparwithseverecourseofcovid19
AT bessonovatatiana bnt162b2mrna1273andsputnikvvaccinesinducecomparableimmuneresponsesonaparwithseverecourseofcovid19
AT kireevamaria bnt162b2mrna1273andsputnikvvaccinesinducecomparableimmuneresponsesonaparwithseverecourseofcovid19
AT mazoilya bnt162b2mrna1273andsputnikvvaccinesinducecomparableimmuneresponsesonaparwithseverecourseofcovid19